Human study, secondary analysis

Six-month periodic fasting does not affect somatosensory nerve function in type 2 diabetes patients

A six-month controlled trial of periodic fasting in patients with type 2 diabetes, looking only at nerve function.

Front Endocrinol (Lausanne), 2023. Kender Z, et al.

Funding and competing interests (as published with the paper): The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. L-Nutra, as funder of the fasting-mimicking diet used in this study, has no role in the design or conduct of the study nor in the preparation, review, or approval of the manuscript. VL is founder and shareholder of L-Nutra; his shares are destined to the Create Cures Foundation and other charitable and research organizations. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.

Read the full study

Opens the journal or PubMed page in a new tab. Some journals require a subscription.

Study type
Human clinical trial
Journal
Front Endocrinol (Lausanne)
Published
2023
Authors
Kender Z, et al.
DOI
10.3389/fendo.2023.1143799
PubMed ID
37251671

Summary

Patients with type 2 diabetes had their somatosensory nerve function assessed before and after six months of either a Fasting Mimicking Diet (FMD) or a control Mediterranean diet. The authors measured neuropathy disability and symptom scores, nerve conduction velocity and quantitative sensory testing. A small number of participants in each group also had diffusion-weighted MR neurography of the right leg before and after the diet period.

The authors reported that clinical neuropathy scores did not differ between the groups at baseline and did not change after the intervention, and that 64% of the Mediterranean diet group and 47% of the FMD group already had diabetic neuropathy. They reported that sural nerve sensory measures were comparable between the groups. They reported a decrease in tibial motor nerve conduction velocity in the Mediterranean diet group with no change in the FMD group, an increase in tibial compound motor action potential in the FMD group, and a decrease in heat pain threshold in the Mediterranean diet group with no change in the FMD group. Changes in thermal detection, mechanical detection and mechanical pain did not differ between the groups, and the imaging measures did not change in either group. The authors concluded that six-month periodic fasting was safe for nerve function and had no detrimental effect on it.

This is a study in a patient group with type 2 diabetes, around half of whom already had diabetic neuropathy, not a study of a general wellness population. L-Nutra, Prolon's parent company, funded the Fasting Mimicking Diet used in this study. The reported finding is an absence of harm rather than a benefit. The two diet groups were small and only a handful of participants in each underwent the imaging component. The abstract does not state that participants were randomly assigned to the two diets, so the comparison between them should be read with that in mind.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.